Singapore's medicines regulator. It registers a new medicine by full evaluation, by abridged evaluation if at least one regulator has approved it, or by verification if at least two of its six reference agencies have.
The Health Sciences Authority registers therapeutic products in Singapore. Its evaluation routes page describes three routes for a new drug: full evaluation for a product no regulator has approved; abridged evaluation for a product approved by at least one drug regulatory agency; and verification for a product approved by at least two of its reference agencies (the US FDA, the European Medicines Agency through the centralised procedure, Health Canada, the UK MHRA, Swissmedic and Australia's TGA), within three years by the chosen primary agency, with the unredacted assessment reports. A company may ask for priority review for a medicine for a serious life-threatening condition that meets a local unmet need, and the page names cancer among the conditions of local public health concern. The Ministry of Health's financing FAQs say a drug generally counts as clinically proven for the Cancer Drug List if it is registered with the authority for the indication.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-11-19.
Matched to Health Sciences Authority, including child institutions. 4 works · 42 citations · 75% open access · 0% clinical trials · 50% reviews.
| Work | Journal | Year | Citations |
|---|---|---|---|
| Mechanism of action, potency and efficacy: considerations for cell therapies | Journal of Translational Medicine | 2024 | 24 |
| Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation | Transplantation and Cellular Therapy | 2025 | 9 |
| Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT) 10.1016/j.retram.2025.103515 · open access | Current Research in Translational Medicine | 2025 | 9 |
| NAVIGATING CHALLENGES IN AUTOMATED CELL PROCESSING FOR CELL AND GENE THERAPY PRODUCTS: INSIGHTS FROM A GMP FACILITY IN SINGAPORE 10.1016/j.jcyt.2024.03.281 | Cytotherapy | 2024 | 0 |
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/